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ABSTRACT 
Cancer claims the second largest number of deaths across the globe every year. With the new addition and discoveries in the therapeutic area, there 
are also some serious challenges which come into play. These include the emergence of resistance, malignancy, relapses and some life-threatening 
adverse effects. These challenges further intensify the need to discover better alternatives. Thiosemicarbazones have been explored extensively 
against many resistant and non-resistant forms of cancer in vitro as well as in vivo. Chelation of iron and copper has been attributed to their activity 
as anticancer agents, but recent studies have revealed few more complex mechanisms of their action. With different approaches to target different 
aspects of cancers, they have gained ample attention. Structural variations of these compounds were found to be highly selective in their action.  
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INTRODUCTION 
Thiosemicarbazone is a derivative of imine which is formed when an 
aldehyde/ketone reacts with a thiosemicarbzide through a 
condensation reaction. The presence of the hetero atoms like 
Sulphur and Nitrogen makes these derivatives biologically active. 
Lately, great emphasis is laid on the synthesis and development of 
these derivatives reason being the wide variety of pharmacological 
activities exhibited by them.  
So far, thiosemicarbazones have been shown to exhibit analgesic and 
anti-inflammatory [1], antibacterial [2], anticancer [3] 
anticonvulsant [4] antifungal [5], anti-HIV [6], anti leishmaniac [7], 
anti-malaria [8] neurotropic [9], anti trypanosomal [10], 
antitubercular [11] and antiviral [12] activities. Few 
thiosemicarbazone derivatives have also been shown to produce 
insulin-like effects in vitro [13]. In a recent study, few 
thiosemicarbazone derivatives have been shown to reactivate 
human and rat cholinesterase in vitro and in silico inhibited by an 
organophosphate namely Methamidiphos [14]. Metal complexes of 
thiosemicarbazones have also been shown to be useful in 
radiopharmaceuticals for diagnostic as well as radiotherapy purpose 
[62]. Cu-ATSM (ATSM = diacetyl-bis(N4-methylthiosemicarbazone)) 
is a promising PET (positron emission tomography) tracer for non-
invasive hypoxic tumor imaging [15-18]. The discovery of their 
anticancer properties in 1956 was a great breakthrough in the field 
of cancer while antiviral activity was the next to be discovered with 
their promising efficacy in the treatment of small pox. N-methyl-
isatin-βthiosemicarbazone (methisazone), this drug was able to 
treat patients with herpes simplex virus (HSV) also [19]. Chemically 
thiosemicarbazones have the general structure R1R2CNNHCSNH2, 
while R1 and R2 may be aromatic or heterocyclic systems. The 
electronic and the steric features of the attached ring system or the 
fragments are often found to have an effect on the biological activity 
of the thiosemicarbazone derivatives. 
Cancer is the second largest cause of death across the globe after the 
cardiovascular events. It is a group of diseases involving abnormal 
cell proliferation may or may not having the potential to invade 
other parts of the body as well.[20]. There are more than 100 types 
of cancer known so far which can affect the human population [21]. 
Thus, it is evident that no single drug can be as efficient to treat all 
forms of cancer. Many drugs are now available as chemotherapeutic 
agents against various forms of cancer, however they also possess 
serious side effects while few others have been rendered inactive 
due to the emergence of resistance against them. Thus the need to 
develop new antineoplastic agents with better efficacy and lower 
toxicity profile will always be there. Many new moieties were 
studied for their pharmacological potential against combatting 
cancers and thiosemicarbazones have been one of them. In 1956, it 
was found that these molecules possess significant activity and can 
be exploited further [3]. Since then, these molecules received due 
attention and in recent years one of them, Triapine® (3-
aminopyridine2-carboxaldehyde thiosemicarbazone), is under 
process to be developed as an anticancer drug for cervical cancer 
[22]. Owing to its activity this molecule has made to the phase II of 
the clinical trials [23].  
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Mechanism of action 
 
Fig. 1: Three different challenges to cancer chemotherapy 
targeted by thiosemicarbazones [24] 
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Inhibition of tumor growth 
Several mechanisms of antitumor action of thiosemicarbazones have 
been proposed so far. Topoisomerase IIa and ribonucleotide 
reductase have been proposed as the two primary targets of these 
molecules. For example, they could stabilize cleavable complexes 
formed by topoisomerase II (topoII) and DNA leading to apoptosis. 
The stabilisation occurs as a result of alkylation of thiol residues on 
the topo IIa–DNA complex. [25] Besides, thiosemicarbazones were 
found to inhibit ribonucleotide reductase (RR). RR enzyme catalyses 
the synthesis of deoxyribonucleotides required for DNA synthesis. 
Since deoxyribonucleotides are present in extremely low levels in 
mammalian cells, it is a crucial and rate-controlling step in the 
pathway leading to the biosynthesis of DNA. Mammalian 
ribonucleotide reductase (RR) is composed of two dissimilar 
proteins, (R1), which contains polythiols and (R2), which contains 
non-heme iron and a free tyrosyl radical. Both the R1 and R2 
subunits contribute to the active site of the enzyme. [26] Since 
thiosemicarbazones are known iron chelators and the chelates of 
iron are redox active thus they can destabilize or damage the non-
heme iron-stabilized tyrosyl free radical and thus inhibit the 
catalytic function of RR. 
Inhibition of drug resistance 
Recent studies have linked P-gp (P-glycoprotein) expression to 
increased drug resistance in patients with advanced cancer.[27,28] 
In few other studies it was demonstrated that P-gp expression and 
function is not limited to plasma membrane, but they also mark their 
presence intra-cellularly in lysosomes.[29,30]. In contrast to other 
drug molecules wherein P-gp sequestration renders the drug 
unavailable for action, lysosomal P-gp enhanced the transport of 
thiosemicarbazones into the lysosomes. [29]. This accounted for the 
increased lysosomal damage and cytotoxicity of thiosemicarbazones 
towards P-gp expressing tumor cells [29]. 
Inhibition of metastasis 
Metastasis accounts for the maximum deaths due to cancer. NDRG1 
(N-Myc downstream regulated gene 1) is a metastasis suppressor 
protein [31,32]. It inhibits primary tumor growth, angiogenesis, and 
metastasis [33-35]. Thiosemicarbazones were found to up regulate 
the NDRG1 protein by depleting the iron from tumor cells resulting 
in a state of hypoxia [36, 37]. 
Thiosemicarbazones as anticancer agents 
Ten novel naphthalene substituted thiosemicarbazones were 
prepared and evaluated for their antifungal and anticancer activity 
against pathogenic yeasts and moulds using broth micro dilution 
assay and A549 human lung adenocarcinoma and NIH/3T3 mouse 
embryonic fibroblast cell lines using XTT (2,3-bis-(2-methoxy-4-
nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) test 
respectively. Ames and umuC assays were carried out to determine 
the genotoxicity of the most effective antifungal derivatives. Among 
these ten derivatives compound 1 and 3 (fig. 2) were found to be 
most active anticandidal agents with MIC (Minimum inhibitory 
concentration) values of 125ug/ml when compared to 
ketoconazole with no mutagenic potential, moreover their 
cytotoxic doses were found to be much higher than their effective 
doses. Compound 2 was found to be the most promising anticancer 
agent with its remarkable antiproliferative activity with IC50 value 
of 31.25 ug/ml when compared to cisplatin 16.28 ug/ml against 
A549 cell line [38].  
Two zinc (II) complexes containing cyclohexanone N(4)-methyl 
thiosemicarbazone and cyclohexanone N(4)-phenyl 
thiosemicarbazone were synthesized. The ligands have been shown 
in the fig. 3. The in vitro antitumor activity of the complexes was 
screened on a panel of human tumor cell lines of distinct tissue 
origin viz., Caki-2 (Kidney), MCF-7 (Breast), CaSki (Cervix), NCI-
H322M (Lung) and Co-115 (Colon) (table 1). The cellular 
proliferation was assessed by Sulforhodamine-B (SRB) assay. Both 
the complexes showed promising antitumor activity, however they 
exhibited selectivity which may be attributed to the structural 








Fig. 3: 1-(cyclohexylideneamino)-3-methylthiourea; 1-
(cyclohexylideneamino)-3-phenylthiourea  
 











1 4.4 4.7 4.5 0.77 1.3 
2 2.7 3.2 1.6 3.9 4.3 
 
Four new thiosemicarbazones were synthesised and their efficacy 
was tested against four cell lines, namely pancreas cancer (PANC-1), 
breast cancer (MCF-7) and human colon cancer (HCT-116) as well as 
on the normal mouse fibroblasts NIH/3T3 cells using MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. The 
following compounds (fig. 4) were found to be several times better 
than the standard drugs (5-Flourouracil and Betulinic acid). IC50 
values of compounds in uM and the standard drugs are presented in 
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Table 2: IC50 values of compounds 
Compound  PANC-1 HCT-116 MCF-7 
1 10uM 14.9uM 14.3uM 
2 0.7uM 9.4uM 15.8uM 
5-Flourouracil 96.8uM 21.0uM - 
Betullinic acid - - 44.1uM 
 
Ten thiophene-thiosemicarbazones were synthesised while the 
thiosemicarbazide fragment was kept the only site of substitution. 
These derivatives were tested for their anticancer potential on nine 
human cancer cell lines taking doxorubicin as the positive control. 
All the compounds were found to be mild to moderately active but 
the following compound (fig. 5) was found to be most active in vitro 
and thus was further studied for in vivo activity against Ehlirch solid 
tumour model in mice, wherein this compound was found to be 
inhibiting tumor growth at a low dose of 30 mg/kg. It was also found 
to possess low acute toxicity [41]. 
 
Fig. 5: 1-(4-bromophenyl)-3-[(Z)-[(thiophen-2-yl) 
methylidene]amino]thiourea 
 
Six new isatin thiosemicarbazone derivatives were synthesised and 
their antineoplastic efficacy was evaluated against human colon 
cancer cell line (HCT 116) taking 5-flurouracil as the standard drug. 
Out of the six new derivatives three compounds (fig. 6) were found 
to possess good cytotoxic activity against HCT 116. The IC50 value for 








In a similar study three new thiosemicarbazones were synthesised 
(fig. 7) with vanillin, acetophenone and benzophenone and their 
antiproliferative activity was evaluated against Ehrlich ascites 
carcinoma cells bearing Swiss albino mice. All the test compounds 
were found to possess comparable cytotoxic action with bleomycin 
against EAC in Swiss albino mice. Acetonethiosemicarbazone at a 
dose of 2 mg/kg was found to possess comparable activity to 
bleomycin (0.3 mg/kg). The cell growth inhibition with 
acetonethiosemicarbazone was found to be 88.97% which is much 
closer to inhibtion shown by bleomycin (88.5%) at a dose of 0.3 
mg/kg. The mean survival time were found to be 40.0 and 39.5 d for 








A series of 5,6-disubstituted pyridine-2,3-dione-3-
thiosemicarbazone derivatives was synthesised and their anticancer 
activity was evaluated against three human cancer cell lines 
including MCF-7 (breast adenocarcinoma cell), HCT116 (colon 
carcinoma cell) and BEL-7402 (hepatoma carcinoma cell) keeping 5-
fluorouracil as the positive control. While some of the compounds 
were found to be much better than the reference drug 5-FU (5-fluoro 
uracil), few derivatives have shown selectivity towards the cancer 
cell lines. The given derivative (fig. 8) was found to be the most 
potent [44]. All the compounds were found to possess IC50<7.0uM. 
Polar and electron donating groups as substitutions on the R group 





Acetone thiosemicarbazone was synthesised to evaluate its 
antineoplastic activity against Ehrlich Ascites Carcinoma cells 
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bearing mice. Several parameters like tumour cell growth inhibition, 
tumour weight, survival time, peritoneal cells and haematological 
parameters were monitored. With a net increase in the survival time 
of mice, this derivative was found to significantly inhibit tumour cell 
growth. A Considerable reduction was observed in the tumour 
weight while peritoneal cells and the haematological parameters 
were restored to normal. Lethal dose (LD50) was found to be 20 
mg/kg in the Swiss albino mice while the most effective dose was 
found to be ten times lower than the lethal dose. This study revealed 
that thiosemicarbazones were active both in vitro and in vivo as well 
with low toxicity to the host [45]. 
In a further study a series of ketone N-4 substituted 
thiosemicarbazones and their Ruthenium (II) arene complexes were 
synthesised. These new derivatives were evaluated for their 
anticancer activity against two human cancer cell lines SGC-7901 
(gastric carcinoma), BEL-7404 (liver carcinoma), and HEK-293T 
(human embryonic kidney) cell lines. Cisplatin, carboplatin and 
oxaliplatin were taken as the standard controls, the given two 
ligands (fig. 9) were found to be most active against SGC-7901 cell 
line with IC50 values of 17.0uM and 17.5uM for 1 and 2 respectively, 
while they have shown significant selectivity and cytotoxicity 
towards BEL-7404. All the complexes were found to be more active 
than carboplatin against BEL-7404 cell [46]. 
 
Fig. 9: 1-phenyl-3-[(E)-(1-phenylethylidene)amino]thiourea; 1-
phenyl-3-[(propan-2-ylidene)amino]thiourea 
 
Two 4-phenyl-3-thiosemicarbazone ligands (fig. 10), and their 
ruthenium (II) complexes were synthesized and characterized. DNA 
binding ability of the compounds was confirmed by absorption 
spectroscopy which indicated that the compounds bind to DNA via 
intercalation. These derivatives were assayed for their cytotoxic 
potential against HeLa and MCF-7 cell lines wherein they were found 
to have good cytotoxic action with low IC50 values of 18.60 and 







Ten novel benzaldehyde thiosemicarbazone complexes of platinum 
were synthesised. The cytotoxic effects of these complexes, 
examined on the human leukaemia cell line HL-60 and human 
lymphoma cell line U-937, have shown that all the complexes are 
cytotoxic in nature and their IC50 values indicate their potential use 
as antitumor agents. The IC50 values of complexes for HL-60 were in 
the range 140-4.0uM while for U-937 it was in the range 45-5.0uM. 
Four drugs were kept as standard namely BCNU (Carmustine), 5-FU, 
cisplatin and hydroxyurea. All the complexes were better than 
hydroxyurea against both the cell lines. [48]. Ligands of the 
complexes have been shown here. (fig. 11) 
 






New polymeric copper (II) complexes with two tridentate 
thiosemicarbazone ligands containing substituted pyrazolone 
moiety were synthesized (fig. 12) and characterized. Complexe of 
the compound 3 was found to have significantly higher cytotoxic 
potential in comparison to cisplatin in inhibition of several cell lines 
HL60 (Human promyelocytic leukaemia cell line), REH (acute 
lymphocytic leukaemia cell line), C6 (rat glioma cell line), L929 
(mouse fibroblast cell line) and B16 (melanoma cell line). IC50 
reported for complex of compound 3 was 2.21ug/ml while that for 
cisplatin was 14.36Ug/ml against REH cell line. The results obtained 
on the basis of flow cytometry indicated that apoptosis could be 










Six new benzoyl thiosemicarbazone analogues of isoquinoline and 
related compounds were prepared to evaluate their cytotoxic and 
antimalarial activities. Four human cancer cell lines were employed 
to check cytotoxic activity namely HuCCA-1(human 
cholangiocarcinoma cell line), HepG2 (liver carcinoma cell line), 
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A549 (small cell lung cancer) and MOLT-3 (human malignant T-
lymphoblastic cell line). All the new derivatives prepared were 
found to possess significant cytotoxic activity against the cell lines. 
The given derivative (fig. 13) was found to possess greatest cytotoxic 
action with IC50 values of 0.03, 4.75, 0.04 and 0.004ug/ml against 
HuCCA-1,HepG2,A549 and MOLT-3 cell lines respectively, while 
doxorubicin and etoposide were kept as the reference drug for the 
cancer cell lines. Also it was found to be most active against P. 
falciparum with IC50 in the range 10-7 to 10-6M, among all other 
derivatives prepared keeping chloroquine hydrochloride as the 
standard drug [50]. 
 
 
Fig. 13: 1-phenyl-3-[(Z)-[phenyl (pyridin-2-
yl)methylidene]amino]thiourea 
 
Seven new 2-acetylpyridine thiosemicarbazone derivative were 
synthesised (fig. 14) and their antineoplastic potential was 
evaluated against two malignant glioma cell lines, namely rat glioma 
RT2 cells and Human glioma T98 cells. These new derivatives were 
found to be active against both the cell lines but they were found to 
inhibit RT2 cell lines the more. These derivatives were found to 
exert good cytotoxic action in 24-1.4nM and 50.0-1nM dose ranges 
for RT2 and T98 glioma cells respectively. The IC50 value for the 
standard drug cisplatin were found to be 5uM and 17uM for RT2 and 
T98 cells respectively. These derivatives were found to exert 
haemolytic action at much higher concentrations indicating a good 












13 novel (-)-a-bisabolol based thiosemicarbazones (fig. 15) were 
synthesised and evaluated against eight different human cancer cell 
lines namely leukaemia (K-562), melanoma (UACC-62), breast 
(MCF7), breast resistant (NCI-ADR), lung (NCI-460), ovarian 
(OVCAR), prostate (PCO-3) and colon (HT-29) taking doxorubicin as 
the standard drug. The given two derivatives were found to be most 
active among the others in the series and were more cytotoxic to the 
breast resistant (NCI-ADR) cell lines than the other cell lines with 






Six new compounds namely 2-Benzoylpyridine-N (4)-tolyl 
thiosemicarbazones and their palladium(II) complexes were 
synthesised and studied for their Cytotoxicity against leukaemia 
cells. Three N(4)-tolyl derivatives namely o-tolyl m-tolyl p-tolyl (fig. 
16) and their palladium complexes were prepared and tested 
against HepG2 (human hepatoma), Jurkat (immortalized line of T 
lymphocyte), HL60 (human promyelocytic leukaemia) and HL60. 
Bcl-XL (human promyelocytic leukaemia ectopically expressing the 
anti-apoptotic protein Bcl-XL that confers resistance to cytotoxic 
stimulus) human cancer cell lines. Cisplatin was taken as the 
reference drug, HL60 was found to be more susceptible to these 
derivatives than the other cell lines, In contrary to the previously 
reported data ligands were more cytotoxic than their palladium 
complexes. O-tolyl derivative was found to be the most active against 
three cell lines tested. The IC50 values of the ligands have been 
shown in the table 3 [53]. 
Table 3: IC50 values of the synthesised compounds in uM [53] 
Compound Jurkat HL60. Bcl-XL HL60 
1 0.015 0.019 0.0095 
2 0.017 0.038 0.0059 
3 0.034 0.028 0.014 
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Iron (III) Complex of 2-acetylpyrazine N (4)-methyl-
thiosemicarbazone were synthesised (fig. 17) and their antitumor 
activity was studied against K562 leucocythemia and BEL7402 liver 
cancer cell lines. Both the complex and the free ligand were 
assayed for their cytotoxic activity wherein the complex was found 
to be more active than the free ligand. The complex showed a 
lower IC50 value (13.7µ M for K562, 38.6µ M for BEL7402) than the 









2-pyridinoformamide-derived thiosemicarbazones ligands (fig. 18) 
and their iron complexes were synthesised and their antineoplastic 
activity was evaluated against Artemia salina taking lapachol as the 
standard drug. LD50(lethal dose) was calculated for all the ligands 
and the complexes were determined. Fe(III) complex of ligand 2 was 
found to possess a low LD50 value of 14.12uM. Rest all derivatives 
and their complexes were found to be more active than the standard 
drug itself [55]. 
Four new benzaldehyde thiosemicarbazone (fig. 19) derivatives and 
their palladium(II) and platinum(II) complexes were synthesised to 
study their cytotoxic action on the following cell lines: H460 (human 
lung large cell carcinoma), ME180 (human cervix epidermoid 
carcinoma), M-14 (human amelanotic melanoma), DU145 (human 
prostate carcinoma), MCF-7 (human breast adenocarcinoma), HT-29 
(human colon adenocarcinoma), PC3 (human prostate carcinoma), 
and K562 (human chronic myelogenous leukemia). The platinum (II) 
complexe of compound 1 was found to possess greater cytotoxic 
action than cisplatin in the human leukaemia cell line. IC50 values in 
uM for the Pt(II) complex of compound 1 are shown in the table 4. 
Also, the complexes were found to be more active than the 
individual ligands [56]. 
 





Nine long chain aliphatic thiosemicarbazones and their nickel 
complexes were synthesised with the aim to test their effect on 
histiocytic lymphoma U937 cell proliferation. Only one ligand (fig. 
20) and its nickel complex were selected on solubility basis for the in 
vitro assay. Though the ligand itself was ineffective, its Ni(II)complex 
showed good antiproliferative (IC50=3.46uM) activity against the 
U937 cell line [57]. 
 
Table 4: IC50 values of Pt(II) complex of ligand 1 
Complex/cellline H460 ME180 M-14 DU145 MCF-7 HT-29 PC3 K562 
Pt(II)Ligand1(IC50) 0.09 0.12 0.10 0.08 0.11 0.07 0.08 0.08 
 
Fig. 20: [(E)-heptylidenamino]thiourea 
 
Twenty-six thiosemicarbazones were synthesised via three steps 
starting from hydrazine hydrate and carbon disulphide. The testing 
of anticancer activity of these compounds in vitro against P-388 
(mouse lymphoma cell line), A-549 (small cell lung cancer), and SGC-
7901 (human gastric cancer cell line) shows that the following 
compounds (fig. 21) possess higher inhibitory ability for P-388 and 
SGC-7901. IC50 for compound 2 was found to be as low as 0.032uM 
against SGC-7901 cell line [58]. 
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Thiosemicarbazones are known to possess several biological 
activities owing to the presence of hetero atoms like nitrogen and 
sulphur and the attached aromatic or heterocyclic fragments. Many 
new pharmacological activities have been explored lately and much 
are to be disclosed. However greater emphasis has been led on their 
antineoplastic activities because of the promising and positive 
outcomes of the studies centred on their anticancer potential. They 
have been shown to be active antiproliferative agents in both in vitro 
as well as in vivo.  
In recent studies these derivatives have also been found to possess 
low acute toxicity with no to minimal mutagenic as well as 
teratogenic potential. Thus it can be an advantage over the available 
anticancer drugs which in spite of having good therapeutic 
properties precipitate serious adverse effects like myelosupression 
which calls for discontinuation of use. Owing to structural variations 
these derivatives have also shown selectivity towards particular cell 
lines in in vitro cytotoxic assays. Thus they can be a boon in the field 
of advanced cancer research and deserve further extensive studies 
to be developed as drug candidates for cancer chemotherapy. 
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